Sugi Predict

Sugi Predict / Compounds / SCHEMBL1015430

SCHEMBL1015430

SCHEMBL1015430

COC(=O)c1cc(O)c(OC)cc1N

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 8/20 0.77
▸ GAA P10253 7/20 0.58
▸ POLB P06746 2/20 0.51
▸ ALDH1A1 P00352 6/20 0.50
▸ HSD17B10 Q99714 5/20 0.50
▸ MAPT P10636 3/20 0.50
▸ HPGD P15428 3/20 0.50
▸ CASP1 P29466 2/20 0.50
▸ CASP7 P55210 2/20 0.50
▸ GLA P06280 2/20 0.50
▸ ATM Q13315 1/20 0.50
▸ ABL1 P00519 1/20 0.49
▸ TSHR P16473 2/20 0.47
▸ ALOX15 P16050 1/20 0.47
▸ CFTR P13569 3/20 0.46
▸ RECQL P46063 2/20 0.45
▸ LMNA P02545 2/20 0.45
▸ CYP3A4 P08684 1/20 0.45
▸ CA12 O43570 2/20 0.44
▸ CA1 P00915 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2189622 0.95 KDM4E (0.79) KDM4EGAAPOLBALDH1A1HSD17B10
SCHEMBL31408659 0.87 KDM4E (1.00) KDM4EGAAPOLBALDH1A1HSD17B10
SCHEMBL372600 0.87 KDM4E (1.00) KDM4EGAAPOLBALDH1A1HSD17B10
SCHEMBL13027985 0.85 KDM4E (0.58) KDM4EGAAPOLBALDH1A1HSD17B10
SCHEMBL7853424 0.84 GAA (0.76) KDM4EGAAPOLBALDH1A1HSD17B10
SCHEMBL217191 0.84 KDM4E (0.53) KDM4EGAAPOLBALDH1A1HSD17B10
SCHEMBL12793494 0.84 HTT (0.56) KDM4EGAAALDH1A1HSD17B10MAPT
SCHEMBL28097982 0.83 HSD17B2 (0.55) KDM4EGAAALDH1A1HSD17B10HPGD
SCHEMBL18655513 0.83 KDM4E (0.58) KDM4EGAAALDH1A1HSD17B10MAPT
SCHEMBL3461530 0.83 KDM4E (0.57) KDM4EGAAPOLBHSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116444447-B SOS1 and HDAC double-target quinazoline hydroxamic acid compound as well as preparation method and application thereof 中国药科大学 2023-09-22 — — CN disclosed
EP-4234548-A1 SUBSTITUTED BENZO OR PYRIDOPYRIMIDINE AMINE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Suzhou Zelgen Biopharmaceutical Co., Ltd. (CN) 2023-08-30 — — EP disclosed
CN-116444447-A SOS1 and HDAC double-target quinazoline hydroxamic acid compound as well as preparation method and application thereof 中国药科大学 2023-07-18 — — CN disclosed
WO-2022083657-A1 SUBSTITUTED BENZO OR PYRIDOPYRIMIDINE AMINE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 苏州泽璟生物制药股份有限公司 2022-04-28 — — WO disclosed
US-10053430-B2 RAF kinase modulator compounds and methods of use thereof AMBIT BIOSCIENCES CORP. (US) 2018-08-21 — — US disclosed
EP-2268623-B9 QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORP (US) 2018-02-28 — — EP disclosed
US-20170298029-A1 RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2017-10-19 — — US disclosed
US-9730937-B2 RAF kinase modulator compounds and methods of use thereof AMBIT BIOSCIENCES CORPORATION (US) 2017-08-15 — — US disclosed
US-9718806-B2 Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor ASTRAZENECA AB (SE) 2017-08-01 — — US disclosed
EP-3147281-A1 QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF Ambit Biosciences Corporation (US) 2017-03-29 — — EP disclosed
WO-2007054357-A1 THIAZOLE ANALOGUES AND USES THEREOF 4SC AG (DE) 2007-05-18 — — WO disclosed
EP-1785420-A1 Thiazole analogues and uses thereof 4SC AG (DE) 2007-05-16 — — EP disclosed
WO-2007009524-A1 2-ARYLBENZOTHIAZOLES AND USES THEREOF 4SC AG (DE) 2007-01-25 — — WO disclosed
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof 4SC AG (DE) 2007-01-25 — — US disclosed
EP-1746096-A1 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer 4SC AG (DE) 2007-01-24 — — EP disclosed
WO-2006069740-A1 2, 5 AND 2, 6-DISUBSTITUTED BENZAZOLE ANALOGUES USEFUL AS PROTEIN KINASE INHIBITORS 4SC AG (DE) 2006-07-06 — — WO disclosed
WO-2006066795-A1 2,5- AND 2,6-DISUBSTITUTED BENZAZOLE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS 4SC AG (DE) 2006-06-29 — — WO disclosed
US-20060142570-A1 Benzazole analogues and uses thereof 4SC AG (DE) 2006-06-29 — — US disclosed
EP-1674466-A1 2,5- and 2,6-disubstituted benzazole analogues useful as protein kinase inhibitors 4SC AG (DE) 2006-06-28 — — EP disclosed
US-20060135782-A1 Benzazole analogues and uses thereof 4SC AG (DE) 2006-06-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10053430-B2 RAF kinase modulator compounds and methods of use thereof BRAF, RAF1, ARAF KDM4E 1824/4885GAA 2536/4885POLB 2074/4885
US-20060142570-A1 Benzazole analogues and uses thereof CYP3A5, CYP3A7, CYP3A43 KDM4E 3177/4885GAA 372/4885POLB 2186/4885
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof NR2E1, NR2E3, NR0B2 KDM4E 2243/4885GAA 3053/4885POLB 3623/4885
US-20170298029-A1 RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF BRAF, RAF1, ARAF KDM4E 1824/4885GAA 2536/4885POLB 2074/4885
US-20060135782-A1 Benzazole analogues and uses thereof DCK, SBK3, DAPK3 KDM4E 1159/4885GAA 1654/4885POLB 2168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.